Aurobindo Pharma US unit Lannett gets four USFDA observations
Aurobindo Pharma shares rose over 1% on the BSE after the company said the US FDA conducted a routine inspection of its wholly owned step-down subsidiary, Lannett Company LLC, from 17 to 21 August 2026. The inspection concluded with four observations, adding regulatory compliance risk despite no other consequences being stated.